



ANSWERS FOR CANCER

Genetron Health to Present at Canaccord Genuity 40th Annual Growth Conference

July 29, 2020

BEIJING, July 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, today announced that management will present and host one-on-one meetings at the Canaccord Genuity 40th Annual Growth Conference to be held virtually on August 11-13, 2020.

On Thursday, August 13th, the Genetron management will participate in the following:

- Fireside chat at 8:00 am ET (8:00 pm Beijing time) with Sizhen Wang, Chief Executive Officer
- Panel discussion entitled, "Cancer screening for asymptomatic individuals. Single vs. multi-target testing; different technological approaches; and opportunities/challenges to drive broad-based adoption," at 11:00 am ET (11:00 pm Beijing Time) with Yun-Fu Hu, PhD, Chief Medical Officer

A webcast of the presentation will be available on the "News and Events" page of the Investors section of the Company's website. A replay of each webcast will be available for 30 days following the event. For more information, please visit <https://ir.genetronhealth.com/investors>.

About Genetron Holdings Limited

Genetron Holdings Limited ("Genetron Health" or the "Company") is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may", "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contacts

US:

Hoki Luk

Head of Investor Relations

Email: hoki.luk@genetronhealth.com

Phone: +1 (408) 204-5343

Stephanie Carrington

Westwicke, an ICR Company

Email: Stephanie.Carrington@westwicke.com

Phone: +1 (646) 277-1282

Asia:

Bill Zima

ICR, Inc.

Email: bill.zima@icrinc.com

GenetronIR@icrinc.com

Media Relations Contact

Edmond Lococo

ICR

Email: Edmond.Lococo@icrinc.com

Mobile: +86 138-1079-1408

genetron.pr@icrinc.com